Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Intervention in weight management should begin before the onset of the metabolic syndrome. Therapeutic lifestyle changes (e.g., diet and physical activity) comprise the cornerstone of care for overweight and obese patients. Behavior modification approaches are useful in facilitating adherence to specific dietary regimens. Pharmacotherapy is an option for patients with a BMI >30 kg/m(2) or for those with a BMI of 27 to 30 kg/m(2) and two or more risk factors, who have failed on diet and exercise alone. To date, the U.S. Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine.
Pi-Sunyer
F Xavier
FX
Division of Endocrinology, Diabetes, and Nutrition, Columbia University College of Physicians and Surgeons, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA. fxp1@columbia.edu
D031204:Caloric Restriction; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003503:Cyclobutanes / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000517:prevention & control; D004032:Diet; D018752:Diet, Fat-Restricted; D038441:Diet, Mediterranean; D015444:Exercise; D005247:Feeding Behavior; D005526:Food, Formulated; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000517:prevention & control*; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000628:therapy; D000077403:Orlistat; D010645:Phentermine / Q000627:therapeutic use; D011236:Prediabetic State / Q000188:drug therapy; D040242:Risk Reduction Behavior; D015431:Weight Loss
D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; D010645:Phentermine; C058254:sibutramine